Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI4KNB)

Drug Name
N-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide Drug Info
Synonyms
CHEMBL251369; N-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide; AC1MH48W; MLS001162447; SCHEMBL13148062; cid_2996093; N-[2-(morpholin-4-yl)phenyl]-5-nitrofuran-2-carboxamide; MolPort-002-305-194; HMS2967E08; ZINC4842600; STK355602; BDBM50223675; AKOS000458368; MCULE-3330873928; SMR000670465; VU0465060-1; N-(2-morpholin-4-ylphenyl)-5-nitro-2-furamide; AP-970/43481542; N-[2-(4-morpholinyl)phenyl]-5-nitro-2-furamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2996093
TTD Drug ID
DMI4KNB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Granulocyte colony-stimulating factor receptor (G-CSF-R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tbo-Filgrastim DML6OE7 Neutropenia 4B00.0 Approved [2]
Pegfilgrastim DM7UP8X Central nervous system neoplasm Approved [3]
Peg-G-CSF DMBKWAF Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
BLZ-945 DMG1LVA Amyotrophic lateral sclerosis 8B60.0 Phase 2 [4]
SBC-014 DMG1VXR Neutropenia 4B00.0 Phase 2 [5]
AX-200 DMTAEMB Cardiovascular disease BA00-BE2Z Phase 2 [6]
MAXY-G34 DMWLIPJ Neutropenia 4B00.0 Phase 2 [7]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [8]
AMG 820 DMB6Q19 Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
MK-6302 DMZUA5C Neutropenia 4B00.0 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Granulocyte colony-stimulating factor receptor (G-CSF-R) TTC70AJ CSF3R_HUMAN Inhibitor [1]

References

1 Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6070-4.
2 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3 Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
5 A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9: 2.
6 Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013 Oct;44(10):2681-7.
7 Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38.
8 National Cancer Institute Drug Dictionary (drug id 747694).
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.